Brief: Talis Biomedical Reports Q3 Revenue Of $200,000
15/11/2021 21:23
Nov 15 (Reuters) - Talis Biomedical Corp TLIS.O :
* Q3 REVENUE $200,000
* QTRLY NET LOSS PER SHARE $1.49
Source text for Eikon: ID:nGNX6hnyjv
Further company coverage: TLIS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talis Biomedical
See all newsBrief: Talis Biomedical Says Nasdaq Believes Co Is 'Public Shell' And Continued Listing Of Its Common Stock Is No Longer Warranted
Brief: Talis Biomedical Says Accepting Voluntary Resignation Of Heinrich Dreismann From Board Effective August 1
Brief: Talis Biomedical Eliminates Andrew Lukowiak As President And Chief Scientific Officer
Talis Biomedical up on plans to explore strategic options, job cuts
Brief: Talis Biomedical Announces Exploration Of Strategic Alternatives And Cost Reduction Plan To Preserve Cash